



US006245776B1

(12) **United States Patent**
Skwierczynski et al.

(10) **Patent No.:** US 6,245,776 B1
(45) **Date of Patent:** *Jun. 12, 2001

(54) **FORMULATIONS AND METHODS FOR TREATMENT OF MUCOSAL ASSOCIATED CONDITIONS WITH AN IMMUNE RESPONSE MODIFIER**

(75) Inventors: **Raymond D. Skwierczynski**, Oakdale, MN (US); **Kenneth R. Phares**, Chapel Hill, NC (US); **Richard L. Miller**, Maplewood, MN (US); **Zheng Jane Li**, Quaker Hill, CT (US); **Michael J. Jozwiakowski**, Stillwater; **Terri F. Busch**, St. Paul, both of MN (US)

(73) Assignee: **3M Innovative Properties Company**, St. Paul, MN (US)

(*) Notice: This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/479,578**

(22) Filed: **Jan. 7, 2000**

Related U.S. Application Data

(60) Provisional application No. 60/115,256, filed on Jan. 8, 1999.

(51) **Int. Cl.⁷** **A61K 31/44**

(52) **U.S. Cl.** **514/293**

(58) **Field of Search** 514/293

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,314,941	4/1967	Littell et al.	.
3,917,624	11/1975	El-Hajj et al.	.
4,689,338 *	8/1987	Gerster 514/293
4,698,348	10/1987	Gerster	.
4,929,624	5/1990	Gerster et al.	.
4,988,815	1/1991	Andre et al.	.
5,037,986	8/1991	Gerster	.
5,175,296	12/1992	Gerster	.
5,238,944 *	8/1993	Wick et al. 514/293
5,266,575	11/1993	Gerster et al.	.
5,268,376	12/1993	Gerster	.
5,346,905	9/1994	Gerster	.
5,352,784	10/1994	Nikolaides et al.	.
5,367,076	11/1994	Gerster	.
5,389,640 *	2/1995	Gerster et al. 514/293
5,395,937	3/1995	Nikolaides et al.	.
5,444,065	8/1995	Nikolaides et al.	.
5,446,153	8/1995	Lindstrom et al.	.
5,482,936	1/1996	Lindstrom	.
5,494,916	2/1996	Lindstrom et al.	.
5,525,612	6/1996	Gerster	.
5,585,612	12/1996	Harp, Jr.	.
5,605,899	2/1997	Gerster et al.	.
5,627,281	5/1997	Nikolaides et al.	.
5,644,063	7/1997	Lindstrom et al.	.
5,648,516	7/1997	Nikolaides et al.	.

5,714,608	2/1998	Gerster .
5,741,908	4/1998	Gerster et al. .
5,741,909	4/1998	Gerster et al. .
5,886,006	3/1999	Nikolaides et al. .
5,977,366	11/1999	Gerster et al. .
6,069,149	5/2000	Nanba et al. .

FOREIGN PATENT DOCUMENTS

0 894 797 A1	2/1998	(EP) .
9-208584	8/1997	(JP) .
93-09119	5/1993	(WO) .
97-41884	11/1997	(WO) .
97-48704	12/1997	(WO) .
98-24436	6/1998	(WO) .
99/29693	6/1999	(WO) .
00-06577	2/2000	(WO) .
00-09506	2/2000	(WO) .

OTHER PUBLICATIONS

R. Snoeck, G. Andrei and E. De Clercq, "Specific Therapies for Human Papilloma Virus Infections", *Current Opinion in Infectious Diseases*, 1998, vol. 11, pp. 733–737.

"3M Pharmaceuticals unveils research and development and expansion plans" retrieved from STN INTERNATIONAL, No. 2138, p. 10... (1996).

Harrison, C.J. et al., "Effects of Cytokines and R-837 a Cytokine Inducer on UV-Irradiation Augmented Recurrent Genital Herpes in Guinea-Pigs", *Antiviral Research*, 1991, vol. 15, No. 4, pp. 315–322.

Harrison, C.J. et al., "Modification of Immunological Responses and Clinical Disease During Topical R-837 treatment of Genital HSV-2 Infection", *Antiviral Research*, 1988, vol. 10, No. 4–5, pp. 209–224.

Miller, R.L. et al., Review Article. Imiquimod Applied Topically: A Novel Immune Response Modifier and New Class of Drug, *International Journal of Immunopharmacology*, Jan. 1999 (1999–01), vol. 21, No. 4–5, pp. 1–14.

Chollet, J.L. et al., "Development of a Topically Active Imiquimod Formulation", *Pharmaceutical Development and Technology*, New York, NY, US Jan. 1999 (1999–01), vol. 4, No. 1, pp. 35–43.

(List continued on next page.)

Primary Examiner—Raymond Henley, III

(74) *Attorney, Agent, or Firm*—Mary Susan Howard; Ted K. Ringsred; Robert W. Sprague

(57) **ABSTRACT**

Immune response modifier (IRM) compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo- and oxazoloquinolinamines and pyridinamines, imidazonaphthyridine and tetrahydroimidazonaphthyridine amines—are useful for the treatment of conditions at and below the mucosal surfaces by administering a therapeutically effective amount of such compounds to the mucosal surface. Novel pharmaceutical formulations are provided. In one embodiment, the pharmaceutical formulations are advantageous for treatment of cervical conditions such as cervical dysplasias including cervical intraepithelial neoplasias.